Table 1.
Demographic and clinical data of patients.
| Parameter | |
|---|---|
| Number of patients | 50 |
| Age at diagnosis (years)a | 2.32 (0.10; 15.8) |
| < 1.5 | 16 |
| > 1.5 | 34 |
| Sex (female/male) | 21/29 |
| Bodyweight (kg)a | 12.35 (0.59; 53.6) |
| Risk stratification of patients | |
| Low-risk | 15 |
| High-risk | 35 |
| Cyclophosphamide dose (mg/kg/day) | |
| Rapid COJECb | 10.5–25.5 |
| Infant CO or CADOb | 0.8–2 |
| CADOb (≥ 1.5 years old) | 2.2–2.6 |
| Therapeutic outcome: responders | |
| Complete remission (CR) | 16 |
| Partial remission (PR) | 8 |
| Therapeutic outcome: non-responders | |
| Stable disease (SD) | 9 |
| Progressive disease/exit (PD-Exit) | 17 |
amedian (min; max); bCOJEC cisplatin-vincristine-carboplatin-etoposide-cyclophosphamide, CO cyclophosphamide-vincristine, CADO cyclophosphamide-adriamycin-vincristine.